Eli Lilly and Company (NYSE:LLY) is a stock in focus according to Jim Cramer. The company needs a new use for its GLP-1 drug to avoid a stock pullback to the $700s from its current $825 level.

Eli Lilly develops prescription medicines for various chronic diseases. Cramer highlighted the need for a new indication that insurance companies will cover to ignite the stock’s performance.

While LLY is acknowledged as an investment opportunity, some AI stocks offer greater upside potential with less downside risk. Consider exploring undervalued AI stocks in a free report for potential investment opportunities.

Read more at Yahoo Finance: Jim Cramer on Eli Lilly: “It’s Become Luckless”